KaliVir Immunotherapeutics
PrivateLast Round
Series A
Extension
Aug 19, 2026
Total Funding Raised
$29M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
KaliVir Immunotherapeutics is a biotechnology company developing next-generation oncolytic viral immunotherapy programs for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
KaliVir Immunotherapeutics Comparables
Compare KaliVir Immunotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Accession Therapeutics Limited | 86% | |
| ReIGNITE Therapeutics | 86% | |
| TILT Biotherapeutics | 86% | |
KaliVir Immunotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Aug 19, 2026 | ||||
| Series A | Mar 16, 2022 |
KaliVir Immunotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Investment | Series A Extension |
| Premier Partners | Series A |
| Nextrans | Series A Extension |
| QUAD Investment Management | Series A Extension, Series A |
| Company K Partners | Series A |
| Company K Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 19, 2026
$14M round with participation from QUAD Investment Management and SV Investment.
- Jan 23, 2026
Monthly visitors grew 95% MoM, reaching 1.6K.
KaliVir Immunotherapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about KaliVir Immunotherapeutics's valuation, stock price, and market status.